# Study of ONO-8539 in Patients With Overactive Bladder

> **NCT00876421** · PHASE2 · COMPLETED · sponsor: **Ono Pharmaceutical Co., Ltd.** · enrollment: 435 (actual)

## Conditions studied

- Overactive Bladder

## Interventions

- **DRUG:** Placebo
- **DRUG:** Tolterodine
- **DRUG:** ONO-8539
- **DRUG:** ONO-8539
- **DRUG:** ONO-8539

## Key facts

- **NCT ID:** NCT00876421
- **Lead sponsor:** Ono Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2010-04
- **Final completion:** —
- **Target enrollment:** 435 (ACTUAL)
- **Last updated:** 2012-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00876421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00876421, "Study of ONO-8539 in Patients With Overactive Bladder". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00876421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*